Discontinuation of RAS Inhibitors in Advanced CKD — Has Equipoise Occurred?
The New England Journal of Medicine , Volume 387, pp 2083-2084; https://doi.org/10.1056/nejme2214315
Abstract: Blockade of the renin–angiotensin system (RAS) is renoprotective beyond the effect of lowering blood pressure, especially in patients with mild-to-moderate chronic kidney disease (CKD).1,2 However, such renoprotection is far more effective when patients with CKD have proteinuria.1,2 As nephrologists, we struggle about whether to continue prescribing RAS inhibitors to patients with advanced (stage 4 or 5) CKD, given the perceived risks. We hope that stopping such treatment may lead to an increase (however modest) in the estimated glomerular filtration rate (eGFR), and we worry about possible drug-related hyperkalemia and other adverse events if RAS inhibition is continued. Although recent retrospective . . .
Keywords: chronic kidney disease / blood pressure / RAS / treatment / sup / hope / retrospective / nephrologists / hyperkalemia / stopping
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Click here to see the statistics on "The New England Journal of Medicine" .